These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 16171950)

  • 1. Phosphodiesterase inhibitors may be indicated in the treatment of postulated vasoactive neuropeptide autoimmune fatigue-related disorders.
    Staines DR
    Med Hypotheses; 2006; 66(1):203-4. PubMed ID: 16171950
    [No Abstract]   [Full Text] [Related]  

  • 2. Does dysregulation of key epigenetic and biochemical pathways occur in postulated vasoactive neuropeptide autoimmune disorders?
    Staines DR
    Med Hypotheses; 2005; 65(6):1154-60. PubMed ID: 16026937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase 4 inhibitors, rolipram and diazepam block the adaptive changes observed during morphine withdrawal in the heart.
    González-Cuello A; Sánchez L; Hernández J; Teresa Castells M; Victoria Milanés M; Laorden ML
    Eur J Pharmacol; 2007 Sep; 570(1-3):1-9. PubMed ID: 17601555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do vasoactive neuropeptide autoimmune disorders explain pyridostigmine's association with Gulf War syndrome?
    Staines D
    Med Hypotheses; 2005; 65(3):591-4. PubMed ID: 16004938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lost in translation; from animal models of pulmonary fibrosis to human disease.
    Maher TM; Wells AU
    Respirology; 2009 Sep; 14(7):915-6. PubMed ID: 19740253
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic and preventive interventions for postulated vasoactive neuropeptide autoimmune fatigue-related disorders.
    Staines DR
    Med Hypotheses; 2005; 65(4):797-803. PubMed ID: 16042995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis.
    Videla S; Vilaseca J; Medina C; Mourelle M; Guarner F; Salas A; Malagelada JR
    J Pharmacol Exp Ther; 2006 Feb; 316(2):940-5. PubMed ID: 16254133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do vasoactive neuropeptides and heat shock proteins mediate fatigue-related autoimmune disorders?
    Staines DR
    Med Hypotheses; 2005; 64(3):539-42. PubMed ID: 15617862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase-4 inhibition and brain tumor growth.
    Schmidt AL; de Farias CB; Abujamra AL; Brunetto AL; Schwartsmann G; Roesler R
    Clin Cancer Res; 2009 May; 15(9):3238; author reply 3238-9. PubMed ID: 19406836
    [No Abstract]   [Full Text] [Related]  

  • 10. Do cytosine guanine dinucleotide (CpG) fragments induce vasoactive neuropeptide mediated fatigue-related autoimmune disorders?
    Staines DR
    Med Hypotheses; 2005; 65(2):370-3. PubMed ID: 15922114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis.
    Moore CS; Earl N; Frenette R; Styhler A; Mancini JA; Nicholson DW; Hebb AL; Owens T; Robertson GS
    J Pharmacol Exp Ther; 2006 Oct; 319(1):63-72. PubMed ID: 16809479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase 4 inhibitors modulate beta2-adrenoceptor agonist-induced human airway hyperresponsiveness.
    Faisy C; Risse PA; Naline E; Guerot E; Fagon JY; Devillier P; Advenier C
    Life Sci; 2006 Oct; 79(20):1929-35. PubMed ID: 16820175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventive effect of rolipram, a phosphodiesterase 4 enzyme inhibitor, on oxidative renal injury in acute ascending pyelonephritis model in rats.
    Görür S; Celik S; Hakverdi S; Aslantaş O; Erdoğan S; Aydin M; Ocak S; Namik Kiper A
    Urology; 2008 Oct; 72(4):743-8. PubMed ID: 18554698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rolipram, a specific type-4 phosphodiesterase inhibitor, inhibits cyclophosphamide-induced haemorrhagic cystitis in rats.
    Sakura M; Masuda H; Matsuoka Y; Yokoyama M; Kawakami S; Kihara K
    BJU Int; 2009 Jan; 103(2):264-9. PubMed ID: 18710439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
    Harada D; Tsukumo Y; Takashima Y; Manabe H
    Eur J Pharmacol; 2006 Feb; 532(1-2):128-37. PubMed ID: 16442096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Parkinson's disease an autoimmune disorder of endogenous vasoactive neuropeptides?
    Staines DR
    Med Hypotheses; 2007; 69(6):1208-11. PubMed ID: 17562359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model.
    Harada D; Ikeda Y; Nosaka Y; Kobayashi K; Manabe H
    J Dermatol Sci; 2008 Sep; 51(3):215-9. PubMed ID: 18539440
    [No Abstract]   [Full Text] [Related]  

  • 18. Rolipram, a phosphodiesterase inhibitor, in the treatment of two male patients with congenital nephrogenic diabetes insipidus.
    Bichet DG; Ruel N; Arthus MF; Lonergan M
    Nephron; 1990; 56(4):449-50. PubMed ID: 1964202
    [No Abstract]   [Full Text] [Related]  

  • 19. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.
    Giampà C; Middei S; Patassini S; Borreca A; Marullo F; Laurenti D; Bernardi G; Ammassari-Teule M; Fusco FR
    Eur J Neurosci; 2009 Mar; 29(5):902-10. PubMed ID: 19291221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rolipram and diazepam on the adaptive changes induced by morphine withdrawal in the hypothalamic paraventricular nucleus.
    Núñez C; González-Cuello A; Sánchez L; Vargas ML; Milanés MV; Laorden ML
    Eur J Pharmacol; 2009 Oct; 620(1-3):1-8. PubMed ID: 19683523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.